Page last updated: 2024-11-12
bms 747158-02
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
BMS 747158-02: a PET myocardial imaging agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 11405965 |
CHEMBL ID | 2107799 |
SCHEMBL ID | 12453262 |
MeSH ID | M0517688 |
Synonyms (33)
Synonym |
---|
[18f]bms-747158-01 |
2-tert-butyl-4-chloro-5-[4-(2-[18f]fluoroethoxymethyl)-benzyloxy]-2h-pyridazin-3-one |
BMS-747158-02 , |
bms 747158-02 |
flurpiridaz f 18 (usan) |
D10009 |
CHEMBL2107799 |
fluripiridaz f 18 |
bms-747158 |
flurpiridaz f-18 |
flurpiradaz f 18 [usan:inn] |
4-chloro-2-(1,1-dimethylethyl)-5-((4-((2-((sup 18)f)fluoroethoxy)methyl)phenyl) methoxy)pyridazin-3(2h)-one |
ty3v24c029 , |
flurpiridaz, f-18 |
863887-89-2 |
flurpiridaz (18f) |
flurpiridaz (18f) [inn] |
flurpiridaz f 18 |
bms747158 |
flurpiridaz f 18 [usan] |
flurpiradaz f 18 |
3(2h)-pyridazinone, 4-chloro-2-(1,1-dimethylethyl)-5-((4-((2-(fluoro-(sup 18)f)ethoxy)methyl)phenyl)methoxy)- |
unii-ty3v24c029 |
SCHEMBL12453262 |
flurpiridaz ((1)f) [inn] |
flurpiridaz (18f) [who-dd] |
3(2h)-pyridazinone, 4-chloro-2-(1,1-dimethylethyl)-5-((4-((2-(fluoro-18f)ethoxy)methyl)phenyl)methoxy)- |
2-tert-butyl-4-chloro-5-((4-((2-(18f)fluoroethoxy)methyl)phenyl)methoxy)pyridazin-3(2h)-one |
DTXSID00235517 |
18f-flurpiridaz |
2-tert-butyl-4-chloro-5-[[4-(2-(18f)fluoranylethoxymethyl)phenyl]methoxy]pyridazin-3-one |
flurpiridaz (18f); flurpiridaz f 18 |
Q27290481 |
Research Excerpts
Toxicity
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (7)
Research
Studies (30)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (16.67) | 29.6817 |
2010's | 20 (66.67) | 24.3611 |
2020's | 5 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.25
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.25) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 6 (16.67%) | 5.53% |
Reviews | 5 (13.89%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 25 (69.44%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |